金十数据7月18日讯，野村发表报告，预测康方生物(09926.HK)中期收入按年升42%至14.5亿人民币，低 于市场预期3%。该行料开坦尼及依达方销售加快，中期收入分别为8亿及6亿元人民币。中期经营开支 料为13亿元人民币，预期整体中期股东应占亏损800万人民币，接近收支平衡，对比去年上半年及下半 年各录亏损2.39亿及2.76亿元人民币。该行料公司下半年收入19亿人民币，受开坦尼及依达方销售推 动，下半年料录净利润2.71亿人民币。该行下调对公司今年收入预测9.6%，基于下调对安尼可销售及协 作收益预测，全年净利润预测上调97.2%，基于更高毛利率假设，对康方生物目标价由99.66港元上调至 120.64港元，维持中性评级。 野村预测康方生物下半年亏转盈 上调目标价至120.64港元 ...

创业最前线 . 创业有道·创新中国｜长期关注中国科技创新经济市场，提供更有价值的创投科技报道。 作者 | 孟祥娜 来源 | 创业最前线 导 语： 康方生物重庆销售人员通过伪造研究立项文件及医院伦理批件等材料，以研究者发起 的药品上市后临床研究的名义，从公司骗取了若干药物。 近日，重庆巫山县肿瘤患者李某美求医购药的经历，将创新药企康方生物推向舆论的风口浪尖。 以下文章来源于创业最前线 ，作者孟祥娜 据大象新闻6月2日报道，李某美经医生推荐，耗费79320元购入卡度尼利单抗注射液，在使用的约 70支药物中，仅有6支为正规上市药品、5支标注"慈善基金会捐赠"，其余竟均为严禁流入市场的临 床研究用药。 面对质疑，康方生物迅速回应，坚称从未向患者收取临床研究药物费用，强调销售人员也未从中获 利，直指"花钱购买临床研究用药"是子虚乌有。 戏剧性的是，就在争议持续发酵之时，康方生物6月5日宣布重大喜讯：卡度尼利联合含铂化疗（联 合 或不联合贝伐珠 单抗）一线治疗宫颈癌的新适应症获批，填补国内该领域免疫治疗空白，标志 着这款药物拿下第三项全人群适应症。 实际上，早在2022年6月，卡度尼利便获批用于既往接受含铂化疗治疗失败的 ...

Market Overview - Recent improvement in US stock market sentiment attributed to Trump's successful Middle East visit [1] - Hong Kong stock market remains sluggish with average trading volume around 220 billion, failing to exceed 300 billion for a breakthrough [1] - Both markets are experiencing weakness due to lack of new stimuli following US-China talks, with a focus on stability in policy adjustments [1] Company Developments - BYD announced the establishment of its European headquarters in Budapest, Hungary, with a total investment of 100 billion HUF (approximately 24.8 million euros), creating 2,000 jobs [3] - The new headquarters will focus on sales, after-sales, vehicle certification, and local design, marking a significant step for BYD in the European market [3] - Netease reported strong financial results, maintaining growth despite the absence of new hits, indicating a healthy industry environment [5] Regulatory Changes - A new mandatory national standard for light vehicle automatic emergency braking systems has been drafted, expanding its applicability to N1 class commercial vehicles [4] - This change is expected to significantly benefit companies like Nanchang Special Vehicle Co., which has been a leader in this technology since 2017 [4] Financial Performance - Tencent and Alibaba reported stable earnings with approximately 10% revenue growth, while JD.com faced a decline of over 4% due to potential losses in local services [4] - China Biopharmaceutical is projected to achieve a revenue of 28.87 billion yuan (+10.2%) in 2024, with a notable increase in innovative drug approvals [11][12] - The company has received FDA approval for its first innovative drug in the US, marking a significant milestone [11] Market Trends - The gaming industry shows resilience with increased engagement despite economic downturns, as evidenced by Netease's stock surge of over 13% [5] - The restaurant sector is also performing well, with companies like Zhou Hei Ya and Guoquan showing positive trends [6] - The stock market is witnessing varied attitudes towards technology stocks, with notable movements from major investors like Buffett and Soros [6]

邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 国产创新药闪耀 ASCO [Table_ReportType] 医药生物行业周报（4 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_ReportDate] 2025 年 04 月 28 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 21 日-4 月 25 日）医药生物收 涨 1.16%，跑赢 wind 全 A（1.15%）和沪深 300（0.38%）。 从板块来看，医疗研发外包（6.34%）和原料药（4.72%） 部分个股一季报表现亮眼，涨幅居前，血液制品（- 3.26%）和疫苗（-6.38%）延续上周跌势。从个股来看， 永安药业（31.4%）、舒泰神（28.4%）和尔康制药（2 ...

[Table_ReportDate] 2025 年 04 月 28 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 国产创新药闪耀 ASCO [Table_ReportType] 医药生物行业周报（4 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（4 月 21 日-4 月 25 日）医药生物收 涨 1.16%，跑赢 wind 全 A（1.15%）和沪深 300（0.38%）。 从板块来看，医疗研发外包（6.34%）和原料药（4.72%） 部分个股一季报表现亮眼，涨幅居前，血液制品（- 3.26%）和疫苗（-6.38%）延续上周跌势。从个股来看， 永安药业（31.4%）、舒泰神（28.4%）和尔康制药（2 ...

Core Viewpoint - China National Pharmaceutical Group's PD-1 monoclonal antibody, Anike (Paimupili injection), has received FDA approval for treating recurrent or metastatic nasopharyngeal carcinoma (NPC) as a first-line therapy and for patients who have failed platinum-based chemotherapy [1][2] Company Summary - Anike is the first innovative drug product from China National Pharmaceutical Group to be approved in the U.S. market [1] - The drug has already been approved for four indications in China, including first-line and subsequent treatment for advanced NPC, and two additional indications for lung cancer and Hodgkin lymphoma [1] - The FDA previously granted breakthrough therapy designation, orphan drug status, and fast track designation for Anike in treating NPC [2] - The CEO of China National Pharmaceutical Group emphasized that the U.S. approval reflects the alignment of China's innovative drug development with international standards and aims to provide new immunotherapy options for NPC patients globally [2] Industry Summary - In 2018, there were approximately 129,000 new cases of NPC globally, accounting for 0.7% of all cancer diagnoses [3] - Over 70% of NPC patients are diagnosed at an advanced stage, and those with recurrent/metastatic NPC have a poor prognosis, with a median overall survival of less than 20 months [3] - There is a significant unmet clinical need for effective treatments for advanced NPC patients [3]